Literature DB >> 14568261

Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, L-amino acid-defined diet, accelerates motility of hepatoma cells.

Masaaki Onaga1, Akio Ido, Satoru Hasuike, Hirofumi Uto, Akihiro Moriuchi, Kenji Nagata, Takeshi Hori, Katsuhiro Hayash, Hirohito Tsubouchi.   

Abstract

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is closely associated with chronic liver diseases, particularly cirrhosis. However, the genes involved in hepatocarcinogenesis in the context of developing cirrhosis remain unknown. This study aims to identify genes associated with early cirrhosis-associated hepatocarcinogenesis.
METHODS: We examined genes differentially expressed between the livers of normal rats and rats fed a choline-deficient, L-amino acid-defined (CDAA) diet using suppression subtractive hybridization. We examined both the expression in the liver and HCC tissues of osteoactivin (OA), isolated in this screen, and its effect on invasiveness and metastasis.
RESULTS: OA mRNA was strongly expressed in the livers of rats fed the CDAA diet for 1-3 months. Moderate expression was sustained for 18 months. OA overexpression increased the invasiveness and metastasis of rat hepatoma cells in vitro and in vivo. In humans, OA expression was not detectable in normal liver tissues. While OA transcripts were detectable in cirrhotic nontumorous liver tissues surrounding HCCs, the majority of HCC tissue samples exhibited higher levels of OA expression than the surrounding normal tissue.
CONCLUSIONS: These results indicate that OA is a novel factor involved in the progression of HCC via stimulation of tumor invasiveness and metastatic potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14568261     DOI: 10.1016/s0168-8278(03)00361-1

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

1.  Differential expression of glycoprotein non-metastatic melanoma protein B (GPNMB) involved in trichostatin A-induced apoptosis in gastric cancer.

Authors:  Wei-Min Ruan; Yun-Long Li; Gang Nie; Wen-Xue Zhou; Xiao-Ming Zou
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Authors:  Patrick A Ott; Omid Hamid; Anna C Pavlick; Harriet Kluger; Kevin B Kim; Peter D Boasberg; Ronit Simantov; Elizabeth Crowley; Jennifer A Green; Thomas Hawthorne; Thomas A Davis; Mario Sznol; Patrick Hwu
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

Review 3.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.

Authors:  Manisha Taya; Stephen R Hammes
Journal:  Steroids       Date:  2017-10-31       Impact factor: 2.668

4.  Comparison of bone morphogenetic protein-2 and osteoactivin for mesenchymal cell differentiation: effects of bolus and continuous administration.

Authors:  Oneida A Arosarena; Fabiola E Del Carpio-Cano; Raul A Dela Cadena; Mario C Rico; Emeka Nwodim; Fayez F Safadi
Journal:  J Cell Physiol       Date:  2011-11       Impact factor: 6.384

5.  Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature.

Authors:  Tao Wang; Yingbin Ge; Min Xiao; Alfonso Lopez-Coral; Rikka Azuma; Rajasekharan Somasundaram; Gao Zhang; Zhi Wei; Xiaowei Xu; Frank J Rauscher; Meenhard Herlyn; Russel E Kaufman
Journal:  Pigment Cell Melanoma Res       Date:  2012-07       Impact factor: 4.693

6.  ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.

Authors:  April A N Rose; Matthew G Annis; Zhifeng Dong; Francois Pepin; Michael Hallett; Morag Park; Peter M Siegel
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

7.  Intrathecal siRNA against GPNMB attenuates nociception in a rat model of neuropathic pain.

Authors:  Lili Hou; Yanfeng Zhang; Yong Yang; Kai Xiang; Qindong Tan; Qulian Guo
Journal:  J Mol Neurosci       Date:  2014-07-17       Impact factor: 3.444

8.  Correlation analysis of liver tumor-associated genes with liver regeneration.

Authors:  Cun-Shuan Xu; Shou-Bing Zhang; Xiao-Guang Chen; Salman Rahman
Journal:  World J Gastroenterol       Date:  2007-06-28       Impact factor: 5.742

9.  Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Catherine A Billups; Thomas Hawthorne; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2014-06-09       Impact factor: 3.167

10.  Glycoprotein non-metastatic melanoma B expression after hepatic ischemia reperfusion and the effect of silibinin.

Authors:  Adamantios Michalinos; Alexandra K Tsaroucha; Maria Lambropoulou; Dimitrios Schizas; Georgia Valsami; Nikolaos Kostomitsopoulos; Michael S Pitiakoudis; Constantinos E Simopoulos
Journal:  Transl Gastroenterol Hepatol       Date:  2020-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.